List of Excipients in Branded Drug ACULAR LS

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Allergan Inc	ACULAR LS	ketorolac tromethamine	0023-9277	BENZALKONIUM CHLORIDE
Allergan Inc	ACULAR LS	ketorolac tromethamine	0023-9277	EDETATE DISODIUM
Allergan Inc	ACULAR LS	ketorolac tromethamine	0023-9277	HYDROCHLORIC ACID

Acular LS Excipient Strategy and Commercial Opportunities

Last updated: September 9, 2026

Acular LS is a 0.4% ketorolac tromethamine ophthalmic solution used for temporary relief of ocular itching associated with seasonal allergic conjunctivitis. Its commercial position depends less on active-ingredient exclusivity than on formulation performance, preservative tolerability, container design, and ophthalmic-generic execution. The principal excipient opportunity is a differentiated, lower-irritancy product that preserves ketorolac solubility, sterility, drop accuracy, and shelf stability.

What is the Acular LS formulation and which excipients does it contain?

Acular LS contains ketorolac tromethamine at 4 mg/mL in a sterile ophthalmic solution. The labeled inactive ingredients are octoxynol 40, edetate disodium, sodium chloride, sodium hydroxide and/or hydrochloric acid for pH adjustment, purified water, and benzalkonium chloride as preservative.[1]

Component	Formulation role	Commercial relevance
Ketorolac tromethamine	Active pharmaceutical ingredient	Nonsteroidal anti-inflammatory drug for ophthalmic use
Octoxynol 40	Surfactant and wetting agent	Supports uniform wetting and may influence ocular comfort
Edetate disodium	Chelating agent	Binds trace metals and can support preservative and stability performance
Sodium chloride	Tonicity adjustment	Helps bring the solution closer to ocular tolerability
Sodium hydroxide and hydrochloric acid	pH adjustment	Controls solubility, stability, comfort, and preservative performance
Purified water	Vehicle	Aqueous delivery medium
Benzalkonium chloride	Antimicrobial preservative	Enables multidose packaging but creates preservative-tolerability concerns

Acular LS is a relatively simple aqueous formulation. The commercial challenge is not excipient complexity. It is maintaining the product's physical and microbiological performance while reducing ocular surface burden and manufacturing cost.

How does Acular LS differ from standard Acular?

Acular LS contains ketorolac tromethamine 0.4%, while the original Acular ophthalmic solution contained 0.5%. The lower concentration was developed for ophthalmic use with a formulation intended to support tolerability and dosing performance.[1]

The concentration difference creates a product-positioning issue for generic manufacturers. A 0.4% product must match the reference product's concentration and dosage form rather than compete solely as a lower-cost version of 0.5% ketorolac. A manufacturer that launches only 0.5% ketorolac may compete in the same therapeutic class but does not replicate the Acular LS presentation.

What excipient strategy is most attractive for Acular LS?

The strongest strategy is a preservative-reduced or preservative-free formulation with equivalent anti-inflammatory delivery and improved ocular-surface tolerability.

1. Preservative-free single-dose formulation

A preservative-free, unit-dose product would address patients who are sensitive to benzalkonium chloride or who require repeated topical treatment. The main trade-offs are higher packaging cost, greater unit-dose material consumption, more complex filling operations, and reduced convenience compared with multidose bottles.

Commercial targets include:

• Patients with dry eye disease or ocular-surface compromise.
• Postoperative patients receiving multiple topical medicines.
• Patients who experience burning or irritation with preserved products.
• Specialty ophthalmology channels that accept higher unit costs for preservative-free products.
• Institutional buyers seeking lower preservative exposure.

A preservative-free product would require robust single-dose container integrity, extractables and leachables assessment, sterility controls, and a clear in-use labeling strategy.

2. Low-benzalkonium or alternative-preservative multidose product

A multidose bottle with reduced benzalkonium chloride exposure could occupy a middle position between conventional preserved drops and higher-cost single-dose packaging. Alternative preservative systems may include polyquaternium-based systems, oxidative preservatives, or other ophthalmic antimicrobial technologies. Each option introduces compatibility, safety, and regulatory-development requirements.

The opportunity is commercially attractive where patients value bottle convenience but prescriber concern about benzalkonium chloride limits use. The formulation must demonstrate preservative effectiveness under the applicable pharmacopeial and FDA expectations for ophthalmic products.[2]

3. Improved drop-size control

Drop volume has direct consequences for dose consistency, product waste, and ocular exposure. A smaller and more reproducible drop can reduce overflow and improve patient acceptance. Drop-size optimization depends on:

• Nozzle geometry.
• Surface tension.
• Viscosity.
• Bottle material.
• Squeeze force.
• Temperature-dependent rheology.
• Orientation during administration.

The formulation should avoid excessive viscosity if it causes blurred vision or slower drainage. A small increase in viscosity may improve residence time, but the product must remain easy to dispense and compatible with the reference product's administration profile.

4. Enhanced ocular comfort

Octoxynol 40 and benzalkonium chloride are logical focus areas for reformulation. Changes to surfactant concentration, surfactant identity, buffer capacity, osmolality, or preservative system could improve comfort. A reformulator should not assume that removing one excipient automatically improves tolerability. The full formulation can affect pH, surface tension, osmolality, corneal exposure, and preservative activity.

A commercially credible program would evaluate:

• Immediate stinging and burning.
• Conjunctival hyperemia.
• Tear-film disruption.
• Corneal epithelial effects.
• Drop retention and drainage.
• Patient preference in crossover studies.

5. Improved packaging

Packaging is an important excipient-adjacent opportunity. A product may use the same active ingredient and broadly similar excipient system while differentiating through:

• Preservative-free multidose technology.
• One-way valve systems.
• Low-contact dispensing tips.
• Metered-dose ophthalmic pumps.
• Unit-dose blow-fill-seal containers.
• Light-protective bottles where stability data support the claim.
• Tamper-evident and adherence-oriented packaging.

The packaging system becomes part of the product's regulatory control strategy. It must protect sterility, maintain dose delivery, and remain compatible with the solution over shelf life.

What FDA regulatory pathway applies to Acular LS generics?

Generic ketorolac ophthalmic products generally use the abbreviated new drug application pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must establish pharmaceutical equivalence and bioequivalence or otherwise satisfy the FDA's product-specific requirements for the dosage form.[3]

For an ophthalmic solution, the development package typically centers on:

• Same active ingredient and strength.
• Same dosage form and route.
• Pharmaceutical equivalence.
• Inactive-ingredient safety and suitability.
• Sterility and preservative effectiveness.
• Stability through the proposed shelf life.
• Container-closure integrity.
• Impurity and degradation-product control.
• Comparative product quality and performance.

An excipient change can complicate the ANDA strategy. A product that departs materially from the reference excipient system may require additional justification, safety information, or a different regulatory pathway. A novel delivery system or clinically meaningful formulation change may be more appropriate for a 505(b)(2) application than a conventional ANDA.

Can a preservative-free Acular LS product use the ANDA pathway?

A preservative-free product can be commercially attractive, but the pathway depends on whether the proposed formulation remains pharmaceutically equivalent to the reference listed drug and whether the inactive-ingredient differences are acceptable for the route and dosage form.

If the product removes benzalkonium chloride while retaining the same strength, dosage form, route, and essential performance characteristics, the applicant may pursue an ANDA if FDA requirements are met. If the formulation introduces a new delivery technology, materially changes administration, or relies on new clinical claims, a 505(b)(2) strategy may be more appropriate.

What is the Orange Book and patent status of Acular LS?

Acular LS is an established ophthalmic product with limited apparent opportunity for active-ingredient patent exclusivity. Ketorolac tromethamine ophthalmic products have been marketed for decades, and the core composition is no longer a strong platform for blocking conventional generic entry.

The relevant regulatory questions are:

Issue	Acular LS assessment
Active ingredient exclusivity	Expired for the mature ketorolac ophthalmic product category
New chemical entity exclusivity	Not applicable to the current Acular LS commercial opportunity
Pediatric exclusivity	No product-specific pediatric extension should be assumed without current FDA data
Orange Book patents	Current listing must be verified in the FDA Orange Book; no strategic value should be assigned to an unverified listing
Formulation patents	Potentially relevant only if tied to a specific, enforceable delivery, preservative, packaging, or manufacturing claim
Method-of-use patents	Limited commercial blocking power for a mature topical NSAID absent a narrowly defined, enforceable indication
Generic pathway	Conventional ANDA competition is the central entry risk

FDA's Orange Book identifies approved drug products and, where applicable, patent and exclusivity information.[4] For a mature product such as Acular LS, the principal barrier is usually product quality and manufacturing execution rather than Orange Book exclusivity.

When does Acular LS lose exclusivity and what does generic entry look like?

Acular LS should be treated as open to generic competition rather than as a product protected by a meaningful remaining exclusivity period. Generic entry risk is therefore driven by development timing, FDA review, manufacturing capacity, and market economics.

Generic launch scenarios

Scenario	Product profile	Commercial effect
Basic generic	0.4% ketorolac solution with reference-like excipients	Rapid price erosion and pharmacy substitution
Preservative-free generic	Unit-dose or preservative-free multidose product	Premium pricing and differentiated ophthalmology positioning
Lower-irritancy generic	Reduced or alternative preservative system	Prescriber switching where ocular-surface tolerability matters
Device-led product	Metered or controlled-drop dispenser	Potentially stronger adherence and waste-reduction claims
Multi-strength portfolio	0.4% and 0.5% ketorolac products	Broader channel coverage but greater inventory complexity
Combination strategy	Ketorolac paired commercially with postoperative eye-care products	Cross-selling rather than patent-based exclusivity

Paragraph IV litigation is possible if an ANDA applicant challenges an Orange Book-listed patent. The litigation risk appears structurally low for a mature Acular LS product unless a current listing covers a specific formulation or delivery system. A generic applicant would face greater risk from product-quality deficiencies, inspection findings, or manufacturing delays than from a fundamental patent barrier.

Which companies are challenging or competing with Acular LS?

Competition comes from both ketorolac generics and other ophthalmic nonsteroidal anti-inflammatory products.

Direct competitors

• Generic ketorolac tromethamine ophthalmic solution 0.4%.
• Generic ketorolac tromethamine ophthalmic solution 0.5%.
• Other branded or generic ophthalmic NSAIDs.

Therapeutic substitutes

• Nepafenac ophthalmic suspension, including products marketed for postoperative inflammation.
• Bromfenac ophthalmic solution.
• Diclofenac ophthalmic solution.
• Corticosteroid ophthalmic products, where clinically appropriate.
• Antihistamine or mast-cell stabilizer products for allergic conjunctivitis.

The most relevant commercial comparison is not only price. It includes dosing frequency, preservative exposure, indication, comfort, reimbursement, surgeon preference, and postoperative protocol integration.

How strong is the Acular LS patent estate?

The patent estate is likely weak as a barrier to conventional generic entry and stronger only around narrowly drafted formulation or device improvements.

Patentable opportunity areas

A new sponsor could pursue patents covering:

• Preservative-free multidose delivery.
• Specific alternative-preservative systems.
• Defined surfactant and chelator combinations.
• Reduced-irritancy formulations with specified pH and osmolality ranges.
• Drop-size and nozzle configurations.
• Container-closure systems that preserve sterility after repeated use.
• Manufacturing methods that reduce particulates or degradation products.
• Stabilized ketorolac formulations with extended shelf life.
• Combination packaging with postoperative ophthalmic regimens.

Patent strength depends on claim scope, unexpected performance, enablement, prior art, and freedom-to-operate exposure. A broad claim to ketorolac in an aqueous ophthalmic solution would face substantial prior-art risk. A narrower claim tied to a measurable performance advantage has a better chance of surviving examination and litigation.

What manufacturing and IP barriers affect commercial entry?

The major barriers are operational.

Manufacturing barriers

Ophthalmic solutions require controlled sterile manufacturing, validated filtration or aseptic processing, container-closure integrity, and reliable particulate control. Key risks include:

• Sterility failures.
• Extractables and leachables from plastic components.
• Preservative adsorption to packaging.
• pH drift.
• Precipitation or crystallization.
• Inconsistent drop size.
• Nozzle blockage.
• Bottle leakage.
• Particulate contamination.
• Supply disruption for specialized ophthalmic components.

The highest-value formulation work is usually linked to manufacturability. A technically elegant formulation that cannot be filled consistently at commercial scale has limited value.

Intellectual-property barriers

Freedom-to-operate analysis should cover:

• Formulation composition claims.
• Preservative-free multidose systems.
• Metered-dose pump patents.
• Valve and nozzle designs.
• Blow-fill-seal packaging.
• Sterilization and filling processes.
• Stability-enhancing excipient combinations.
• Brand-specific trade dress and packaging rights.

A new entrant should separate patentability from freedom to operate. A formulation can be patentable while still infringing a third-party dispensing-device patent.

What are the commercial opportunities for Acular LS excipients?

The most actionable opportunities are differentiated products rather than another undifferentiated preserved generic.

Opportunity	Patient or buyer need	Revenue potential
Preservative-free unit dose	Lower preservative exposure	Moderate premium; higher packaging cost
Preservative-free multidose	Convenience with reduced ocular-surface burden	High differentiation if device performs reliably
Reduced-irritancy preserved product	Better tolerability at lower cost	Moderate premium or formulary advantage
Controlled-drop device	Lower waste and better dose consistency	Moderate device-driven differentiation
Stable low-cost generic	Pharmacy substitution and volume	High volume, low margin
Ophthalmology channel portfolio	Broader postoperative and allergy coverage	Higher account value and contracting leverage
Contract-manufactured specialty product	Faster market access without full internal plant buildout	Lower capital burden, lower gross margin

Product-level Acular LS revenue is not a reliable public benchmark for investment decisions because brand, generic, and channel data are often reported at broader portfolio levels. The commercial case should instead be modeled using prescription volume, generic price erosion, reimbursement, preservative-free premium, packaging cost, manufacturing yield, and ophthalmology-channel access.

What licensing deals could support an Acular LS reformulation?

A licensing strategy would most likely involve one of four assets:

1. A preservative-free ophthalmic delivery platform.
2. A multidose sterile-container technology.
3. A lower-irritancy excipient system.
4. A contract manufacturing or fill-finish platform.

The preferred deal structure depends on the asset. A platform owner may seek an upfront payment, development milestones, and royalties. A contract manufacturer may offer capacity reservations and per-unit pricing. A specialty pharmaceutical company may license regional rights for a differentiated ophthalmic product.

The commercial value of a license is highest when the technology provides a documented regulatory advantage, a measurable patient benefit, and freedom to operate in the target markets.

How does Acular LS compare with other ophthalmic NSAIDs?

Product class	Main formulation issue	Differentiation opportunity
Ketorolac 0.4% solution	Preservative exposure and generic price pressure	Preservative-free or comfort-focused delivery
Ketorolac 0.5% solution	Higher-strength positioning and broad generic availability	Cost, dosing, and formulation quality
Bromfenac solution	Brand positioning and dosing convenience	Price and tolerability
Nepafenac suspension	Suspension uniformity and shaking requirements	Solution-based convenience and lower cost
Diclofenac solution	Ocular tolerability and legacy generic competition	Packaging and preservative profile
Corticosteroid drops	Steroid safety and monitoring	Nonsteroidal positioning and targeted use

Acular LS has its best commercial opportunity in a differentiated delivery product, not in a standard preserved generic that competes only on price.

Key Takeaways

• Acular LS is a 0.4% ketorolac tromethamine ophthalmic solution with a conventional aqueous excipient system.
• The labeled excipients include octoxynol 40, edetate disodium, sodium chloride, pH adjusters, purified water, and benzalkonium chloride.
• The strongest reformulation opportunity is preservative-free or reduced-preservative delivery.
• Drop-size control, ocular comfort, container integrity, and sterile manufacturing are central commercial differentiators.
• Acular LS should be approached as a mature product with substantial generic-entry risk and limited reliance on remaining exclusivity.
• Formulation and device patents may support a new product, but broad ketorolac composition claims are unlikely to provide durable protection.
• The best commercial model combines a conventional low-cost generic with a premium preservative-free or device-enabled product.

FAQs

Is Acular LS preservative-free?

No. The labeled Acular LS formulation contains benzalkonium chloride as an ophthalmic preservative.[1]

Can benzalkonium chloride be removed from an Acular LS generic?

Potentially, but removal changes the formulation and packaging strategy. The applicant must establish sterility, stability, preservative-free container performance, and regulatory acceptability for the proposed product.

Is octoxynol 40 an important commercial excipient in Acular LS?

Yes. It contributes to wetting and formulation performance. Its concentration and interaction with other ingredients may affect comfort, surface tension, and drop delivery.

What is the most defensible patent strategy for a new ketorolac ophthalmic product?

A focused patent strategy covering a measurable formulation or delivery advantage is more defensible than a broad claim to ketorolac in an aqueous ophthalmic solution. Preservative-free multidose systems, controlled-drop devices, and defined low-irritancy compositions are potential targets.

Is a biosimilar challenge relevant to Acular LS?

No. Acular LS is a small-molecule ophthalmic drug, not a biologic. Competition proceeds through generic-drug pathways rather than biosimilar approval pathways.

References

1. U.S. Food and Drug Administration. (n.d.). Acular LS (ketorolac tromethamine ophthalmic solution) 0.4% prescribing information. DailyMed.

2. United States Pharmacopeia. (2024). General chapter <51>: Antimicrobial effectiveness testing. U.S. Pharmacopeial Convention.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.